Cancer gene therapy is an emerging field in the treatment of cancer. It involves the use of genes to treat or prevent cancer by targeting specific cancer cells and modifying their behavior. This therapy holds great promise for the treatment of cancer, and the global cancer gene therapy market is expected to grow significantly in the coming years.

Cancer Gene Therapy Market is segmented by Therapy Type (Oncolytic Virotherapy, Gene Induced Immunotherapy, Gene Transfer), by End User Type (Research Institutes, Biopharmaceutical Companies, Diagnostic Centers, Others), and  Region (North America [The USA, Canada, and Mexico], Europe [Germany, France, The U.K., Russia, and Rest of Europe], Asia-Pacific [China, Japan, India, South Korea, and Rest of Asia-Pacific], and Rest of the World [Brazil, Saudi Arabia, Israel, and Others]).

The cancer gene therapy market was estimated at US$ 1.23 billion in 2021 and is expected to grow at a CAGR of 18.3% during 2022-2028 to reach US$ ~11.9 billion in 2028.

Viral gene therapy is expected to dominate the market due to its high efficiency and specificity. It involves the use of viruses as vectors to deliver therapeutic genes into cancer cells. The most commonly used viral vectors include retroviruses, adenoviruses, and lentiviruses. These vectors have been extensively studied and modified to improve their safety and efficacy.

Non-viral gene therapy is also gaining traction in the market due to its lower toxicity and immunogenicity. It involves the use of non-viral vectors such as liposomes, nanoparticles, and plasmids to deliver therapeutic genes. Non-viral vectors have the advantage of being easy to produce, store, and transport, making them attractive for clinical applications.

Breast cancer is expected to dominate the application segment of the market due to its high prevalence worldwide. Breast cancer gene therapy involves the use of genes that target specific breast cancer cells, such as BRCA1 and BRCA2 genes. These genes are associated with an increased risk of breast cancer and can be used to prevent or treat the disease.

Request a sample here:

https://www.stratviewresearch.com/Request-Sample/3135/cancer-gene-therapy-market.html#form

Lung cancer is also a major application segment due to the high incidence and mortality rates associated with this disease. Gene therapy for lung cancer involves the use of genes that target specific mutations in lung cancer cells, such as the EGFR and ALK genes. These genes are mutated in a significant proportion of lung cancer patients and can be targeted using gene therapy.

Hospitals are expected to dominate the end-user segment of the market due to their high patient volume and the availability of specialized infrastructure and expertise. However, clinics and research institutes are also expected to contribute significantly to the market due to the growing interest in gene therapy research and development.

North America is expected to dominate the global cancer gene therapy market due to the high prevalence of cancer in the region and the availability of advanced healthcare infrastructure and technologies. Europe is also expected to contribute significantly to the market due to the growing investment in gene therapy research and development. Asia-Pacific is expected to be the fastest-growing region due to the high incidence of cancer in the region and the growing focus on healthcare infrastructure development.

In conclusion, the global cancer gene therapy market is expected to grow significantly in the coming years due to the increasing prevalence of cancer worldwide and the growing interest in gene therapy research and development. Viral gene therapy is expected to dominate the market due to its high efficiency and specificity, while breast cancer and lung cancer are expected to dominate the application segment. Hospitals are expected to dominate the end-user segment, while North America is expected to dominate the regional market.